A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Indinavir sulfate

Trial Locations (29)

10001

CRIA, New York

10011

St Vincents Hosp and Med Ctr / Div of HIV Med, New York

10016

Anderson Clinical Research, New York

11203

SUNY / Health Science Ctr at Brooklyn, Brooklyn

11355

New York Hosp of Queens / AIDS Ctr, Flushing

12208

Albany Med College / Div of HIV Medicine, Albany

15213

Anderson Clinical Research, Pittsburgh

19107

Thomas Jefferson Univ, Philadelphia

20889

Natl Naval Med Ctr / Special Immunology Clinic, Bethesda

30308

AIDS Research Consortium of Atlanta, Atlanta

Ponce de Leon Ctr, Atlanta

33136

Univ of Miami School of Medicine, Miami

33316

HIV Clinical Research, Fort Lauderdale

35294

1917 Research Clinic, Birmingham

44304

Akron City Hospital, Akron

48201

Univ Health Ctr 7D, Detroit

60611

Northwestern Univ Med School, Chicago

60612

Rush Presbyterian St Lukes Med Ctr, Chicago

64111

Kansas City Free Health Clinic, Kansas City

77098

Houston Clinical Research Network / Southhampton Med Group, Houston

84132

Univ of Utah School Of Medicine / Div of Infec Disease, Salt Lake City

90027

Kaiser Permanente / Infectious Disease, Los Angeles

90048

Tower ID Med Associates, Los Angeles

94110

San Francisco Gen Hosp / UCSF AIDS Program, San Francisco

95814

Ctr for AIDS Research / Education and Service (CARES), Sacramento

02115

Brigham and Women's Hosp, Boston

02118

Boston Med Ctr / Clinical Research Office, Boston

08103

Education & Research Building, Camden

08043

Garden State Infectious Diseases / E I P Kennedy Health Sys, Voorhees Township

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY